Status:
TERMINATED
Early Palliative Care in Metastatic Lung Cancer in Northern France
Lead Sponsor:
University Hospital, Lille
Collaborating Sponsors:
Santelys Association
Novartis
Conditions:
Lung Cancer Metastatic
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Single-center, prospective, controlled, open-label, randomized, two parallel arms comparing early Palliative care versus Standard care in patients with non-small-cell metastatic lung cancer
Detailed Description
144 patients will be included; 72 per arm. * "Standard" Control arm: patient supported by the onco-respiratory service. * Intervention arm: patients benefit from early palliative care in addition to ...
Eligibility Criteria
Inclusion
- Being diagnosed with non-small cell lung cancer
- Proven histologically
- Metastatic proven imaging (MRI, CT Scanner, PET scan)
- Stage IV (any T, any N, M1)
- prior to secondary chemotherapy treatment.
- Age\> 18 years
- PS ≤2
- Patient able to understand the nature, purpose and methodology of the study
- signed Informed consent
Exclusion
- Age \<18 years
- Patient already supported by palliative care
- Patient with an activating EGFR mutation or EML4-ALK rearrangement or ROS1 gene translocation
- Patient under trusteeship / guardianship
Key Trial Info
Start Date :
October 17 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 23 2018
Estimated Enrollment :
71 Patients enrolled
Trial Details
Trial ID
NCT02308865
Start Date
October 17 2014
End Date
February 23 2018
Last Update
July 11 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHRU, Hôpital Claude Huriez
Lille, France, 59000